Vantage Investment Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Vantage Investment Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-61	Closed	-$4K	–	873
2017 Q4	$4K	Buy	61 +6	+11%	+$378	﹤0.01%	709
2017 Q3	$3K	Hold	55	–	–	﹤0.01%	714
2017 Q2	$7K	Hold	55	–	–	﹤0.01%	611
2017 Q1	$6K	Hold	55	–	–	﹤0.01%	617
2016 Q4	$6K	Hold	55	–	–	﹤0.01%	607
2016 Q3	$9K	Hold	55	–	–	﹤0.01%	521
2016 Q2	$8K	Hold	55	–	–	﹤0.01%	567
2016 Q1	$7K	Hold	55	–	–	﹤0.01%	582
2015 Q4	$8K	Hold	55	–	–	﹤0.01%	547
2015 Q3	$9K	Hold	55	–	–	0.01%	531
2015 Q2	$13K	Hold	55	–	–	0.01%	439
2015 Q1	$16K	Hold	55	–	–	﹤0.01%	534
2014 Q4	$9K	Hold	55	–	–	0.01%	527
2014 Q3	$13K	Buy	+55	New	+$14K	0.01%	446

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vantage Investment Advisors's ICPT Position: Q1 2018 in Review

Vantage Investment Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2018, closing a stake of 61 shares — an estimated $4K sold.

Vantage Investment Advisors first reported a position in ICPT in Q3 2014 and held it in 14 quarters. The position peaked at $16K in Q1 2015. 147 funds tracked by Wall St. Rank hold ICPT as of Q1 2018.

Vantage Investment Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Vantage Investment Advisors sold 61 Intercept Pharmaceuticals, Inc. shares in Q1 2018, an estimated $4K.
Vantage Investment Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 14 quarters.
Vantage Investment Advisors's Intercept Pharmaceuticals, Inc. position peaked at $16K in Q1 2015.
147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2018.

Based on Vantage Investment Advisors's 13F filing for Q1 2018, filed 10 May 2018.